Eli Lilly reports promising lung cancer drug results (LLY:NYSE)
Eli Lilly reports promising lung cancer drug results (LLY:NYSE) Seeking Alpha
Онкология
Рак лёгких
393 материалов по теме, собраны автоматически из проверенных источников
🎗️
Онкология
Roche lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS)
Roche lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS) Seeking Alpha
Онкология
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer UT MD Anderson
Онкология
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy AOL.com
Онкология
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy PR Newswire
🎗️
Онкология
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy - The Daily News
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy The Daily News - Jacksonville, NC
🎗️
Онкология
Frontier Medicines reports promising lung cancer drug results in early trial
Frontier Medicines reports promising lung cancer drug results in early trial Seeking Alpha
🎗️
Онкология
Roche says divarasib cut risk of death 44% in lung cancer trial
Roche says divarasib cut risk of death 44% in lung cancer trial Reuters
Онкология
Targeted Combination Improves Lung Cancer Survival: ESMO 2026
Targeted Combination Improves Lung Cancer Survival: ESMO 2026 EMJ
Онкология
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer | Newswise
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer | Newswise Newswise
Онкология
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer Investing News Network
🎗️
Онкология
Advanced lung cancer patients benefit from radiotherapy in addition to standard treatment
Advanced lung cancer patients benefit from radiotherapy in addition to standard treatment The Institute of Cancer Research
Онкология
Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer
Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer The Clinical Trial Vanguard
🎗️
Онкология
Amgen drug combined with immunotherapy extends survival in lung cancer trial
Amgen drug combined with immunotherapy extends survival in lung cancer trial Reuters
Онкология
Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial
Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial Ynetnews